Goldman Sachs Group upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a buy rating to a conviction-buy rating in a research note issued to investors on Friday, The Fly reports.

Other equities analysts also recently issued research reports about the stock. Wedbush upgraded shares of BioMarin Pharmaceutical from a neutral rating to an outperform rating in a report on Thursday. Leerink Swann restated an outperform rating and set a $142.00 price objective (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. SunTrust Banks set a $115.00 price objective on shares of BioMarin Pharmaceutical and gave the company a buy rating in a report on Thursday, October 19th. Piper Jaffray Companies restated a buy rating and set a $113.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, September 21st. Finally, BMO Capital Markets restated a buy rating on shares of BioMarin Pharmaceutical in a report on Friday, September 15th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. BioMarin Pharmaceutical has an average rating of Buy and a consensus target price of $112.35.

BioMarin Pharmaceutical (NASDAQ BMRN) opened at $93.02 on Friday. BioMarin Pharmaceutical has a fifty-two week low of $80.10 and a fifty-two week high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The firm had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. The company’s revenue for the quarter was up 19.4% compared to the same quarter last year. equities analysts expect that BioMarin Pharmaceutical will post -0.64 EPS for the current fiscal year.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total value of $334,495.00. Following the completion of the sale, the executive vice president now owns 49,299 shares in the company, valued at approximately $4,683,405. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,136 shares of company stock worth $2,139,361. 1.85% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Americafirst Capital Management LLC purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth approximately $702,000. IFM Investors Pty Ltd purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth approximately $448,000. Piedmont Investment Advisors LLC purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth approximately $561,000. California Public Employees Retirement System boosted its position in BioMarin Pharmaceutical by 1.6% in the 3rd quarter. California Public Employees Retirement System now owns 332,500 shares of the biotechnology company’s stock worth $30,946,000 after purchasing an additional 5,100 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth approximately $388,000. Institutional investors and hedge funds own 99.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/biomarin-pharmaceutical-bmrn-upgraded-at-goldman-sachs-group/1771193.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

The Fly

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.